Takepron Intravenous 30 mg specified drug-use survey [Hemostatic effect/rebleeding rate]
Not Applicable
- Conditions
- Gastric ulcer, duodenal ulcer, acute stress gastritis, and acute gastric mucosal lesions
- Registration Number
- JPRN-jRCT1080222498
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 900
Inclusion Criteria
Patients with the following diseases for whom oral administration is not feasible:
Gastric ulcer, duodenal ulcer, acute stress gastritis, and acute gastric mucosal lesion (all of which should be accompanied by bleeding)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method